Curated News
By: NewsRamp Editorial Staff
March 19, 2026
Soligenix's HyBryte™ Gains Peer-Reviewed Backing for CTCL Treatment
TLDR
- Soligenix's HyBryte offers a potential first-line treatment advantage for cutaneous T-cell lymphoma with its non-mutagenic mechanism and strong safety profile.
- HyBryte is a synthetic hypericin photodynamic therapy that uses safe visible light to treat cutaneous T-cell lymphoma, with Phase 3 trial results pending in 2026.
- This therapy addresses unmet medical needs for rare disease patients, potentially improving treatment outcomes and quality of life for those with cutaneous T-cell lymphoma.
- Soligenix's HyBryte represents a novel approach using synthetic hypericin and visible light to treat cancer, with clinical data now published in a peer-reviewed journal.
Impact - Why it Matters
This news matters because it represents a critical step forward in treating cutaneous T-cell lymphoma, a rare and often debilitating cancer with limited therapeutic options. The peer-reviewed validation of HyBryte™'s safety and efficacy data enhances its credibility as a potential first-line treatment, which could significantly improve patient outcomes by offering a non-mutagenic, targeted therapy. For the broader medical community, it signals progress in rare disease research, potentially accelerating regulatory approvals and setting a precedent for similar innovations. Investors and stakeholders should note the interim analysis in Q2 2026, which could drive further clinical and commercial momentum for Soligenix, impacting both healthcare and biopharmaceutical markets.
Summary
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in rare diseases, has achieved a significant milestone with the peer-reviewed publication of comprehensive clinical trial data for HyBryte™ (synthetic hypericin) in the journal Expert Opinion on Investigational Drugs. The publication highlights the therapy's promising safety profile, non-mutagenic mechanism of action, and demonstrated efficacy in treating cutaneous T-cell lymphoma (CTCL), a rare form of cancer. This development supports HyBryte's potential as a first-line treatment option as the company advances its ongoing FLASH2 Phase 3 trial, with an interim analysis expected in the second quarter of 2026. The full details are available in the original press release on www.newmediawire.com.
The company's Specialized BioTherapeutics segment is focused on bringing HyBryte™ to market for CTCL, with plans to seek worldwide regulatory approvals upon successful trial completion. Beyond this flagship program, Soligenix is expanding synthetic hypericin into psoriasis treatment and developing other innovative therapies, including first-in-class innate defense regulators for inflammatory diseases like oral mucositis and Behçet’s Disease. Their diverse pipeline underscores a commitment to addressing unmet medical needs in rare and challenging conditions, leveraging novel scientific approaches.
In addition to its oncology and immunology focus, Soligenix's Public Health Solutions business segment is advancing vaccine candidates for threats like ricin toxin, filoviruses (including Marburg and Ebola), and COVID-19 through its CiVax™ program. These efforts are supported by government funding from agencies such as the National Institute of Allergy and Infectious Diseases (NIAID) and utilize the proprietary ThermoVax® heat stabilization platform. For ongoing updates, investors and the public can follow the company's newsroom at https://ibn.fm/SNGX, while full disclaimers are available via the InvestorBrandNetwork website. This multifaceted strategy positions Soligenix at the forefront of biopharmaceutical innovation, with HyBryte™ leading the charge toward new treatment paradigms.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Soligenix's HyBryte™ Gains Peer-Reviewed Backing for CTCL Treatment
